Neutraceutical conglomerate Sami Group is looking at a growth of 20 per cent in sales for the current financial year as it takes new initiatives for expansion.
"We are looking at a growth of 20 per cent for this fiscal year. The company had posted revenues of USD 100 million (over Rs 600 crore) in the last fiscal," Founder Chairman & Managing Director of Sami Group, Muhammed Majeed told PTI.
He was speaking on the sidelines of the launch of a new product - 'Calci D MaxTM' by the company's subsidiary here.
"Around 96 per cent of the group's income comes from exports. The major markets for us are US, Europe and Japan," he added.
When asked about the initiatives the company plans for expansion, Majeed said: "We are increasing the cultivation base for our products in India. We have contract with farmers for their produce and give them buyback guarantees."
The company has six manufacturing units in India and one in US and employees around 1,000 persons in the country.
Bangalore headquartered Sami Group is mainly present in neutraceutical and cosmeceutical products segment and has presence in US, Europe, Japan, Australia, Middle East, South Africa, China, Vietnam and Philippines, among others.
